ACR 2021

axPsA is axSpA is not...!?

No need for methotrexate in ustekinumab treatment in PsA

New treatment alternative in GCA: promising secukinumab data

Dear Doctor: JAKi risk factors and safety profile - is there a class-effect?

ARIAA: prevention study or very early treatment of RA?

IL-17 pathway important for pain in PsA

Pulmonary involvement and possible therapy concepts in RA

Should we use ultra-low-dose rituximab during the pandemic?

Statins reduce cardiovascular risk and​ mortality - with a slight increase in type 2 diabetes risk

Nausea & alopecia with MTX in RA

Tofacitinib is associated with a slightly increased risk of cancer

We need predictors of response for RA treatment

Long awaited - MACE data from ORAL surveillance

Discordance between patients and physicians in RA

Cycling JAKi compared to switching to biologic DMARD in patients with RA

Cardiovascular disease in RA

Abatacept may reduce subclinical inflammation in RA-at risk patients

Quels marqueurs de réponse aux traitements dans la vraie vie ?

Lange erwartet - MACE-Daten zur ORAL Surveillance

Désaccords patient/Médecin : se comprendre pour plus d'efficacité

Abatacept reduce la inflamación subclínica en pacientes con artralgia con riesgo de progresión a artritis reumatoide

Quels effets indésirables peuvent être associés à la prise de MTX ?

Las estatinas reducen el riesgo cardiovascular y la mortalidad, con un ligero aumento en el riesgo de diabetes tipo 2

Skifte mellom JAK hemmere sammenliknet med skifte til biologisk DMARD hos pasienter med RA

Tofacitinid se asocia con un ligero incremento del riesgo de cáncer​

Comparison of composit indices for disease activity in PsA patients

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events

Joint effusions and enthesitis after physical exertion

PET/CT in diagnosis for PsA

Pain differs: Superior effect of IL-17-inhibition vs. TNF in PsA patients with uncontrolled inflammation

Tildrakizumab in PsA

Secukinumab vs TNF-α blockers in enthesitis

Guselkumab: the better ustekinumab?!

Guselkumab in axial symptoms

Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles

Osteoporosis in PsA

Axial PsA MRI data

No need for MTX in ustekinumab-treated patients

Upadacitinib in PsA

Anemia is an issue in PsA - proper treatment possible!

Associazione di livelli di PCR e uso di FANS con gli eventi cardiovascolari

Anämie bei PsA ist ein Thema - effektive Therapie möglich!

Tildrakizumab bei PsA

Schmerz ist nicht gleich Schmerz: Unterschied von IL-17- und TNF-Inhibition

PET-CT zur Quantifizierung der Entzündung

Guselkumab: das bessere Ustekinumab?!

Gelenkergüsse und Enthesitis nach körperlicher Belastung

Osteoporose bei PsA

Previsione di sviluppo di artrite psoriasica in pazienti con psoriasi utilizzando profili di metilazione del DNA

Guselkumab bei axialer Symptomatik

Studio di confronto tra i vari indici compositi per la valutazione di attività di malattia nell'Artrite Psoriasica

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Upadacitinib bei PsA

Datos de RM en APs axial

Secukinumab vs TNF-α Blocker bei Enthesitis

Axial PsA MRI data

Self-monitoring of disease activity with a smartphone app is feasible in routine clinical management

Dose tapering of TNF inhibitors in axSpA

JAK inhibitors - new kids on the block

Inhibidores JAK: nuevas dianas en EspAax

Datos de RM en APs axial

l’auto-monitoraggio di malattia è fattibile nella gestione clinica di routine nei pazienti con Spondiloartrite assiale

Optimización de iTNF en EspAax

JAKi baricitinib successfully mastered phase II study

Not yet a new standard: belimumab + rituximab

Kombination Belimumab und Rituximab noch kein neuer Standard

JAK-Inhibitor Baricitinib in Phase II erfolgreich

Secukinumab in giant cell arteritis

A new therapeutic approach for giant cell arteritis?

PET as a predictor of vascular damage in large-vessel vasculits

Baricitinib in relapsing giant cell arteritis

Secukinumab nell'arterite a cellule giganti

Neuer Therapieansatz für die Riesenzellarteriitis?

Il ruolo della PET nel predire il danno vascolare nelle vasculiti dei grandi vasi

Baricitinib nell'arterite a cellule giganti recidivante

Breakthrough infections after SARS-CoV2-vaccination - national cohort

Immune responses to COVID-19 vaccines

Anticytokine antibodies causing severe microbacterial infection

TNF blockers reduce the antibody response to RNA vaccination

Should we use ultra-low-dose rituximab during the pandemic?

Breakthrough infections after SARS-CoV2-vaccination - global registry

Impact of COVID-19 on patients with rheumatic diseases

Vaccination against Delta variant worse in patients treated with TNF-alpha blocker

Booster with which one if there is no seroconversion?

Analysis of COVID-19 infection among vaccinated patients with rheumatic disease

Durchbruchsinfektionen nach SARS-CoV2-Impfung - globales Register

TNF-Blocker reduzieren Antikörperantwort bei RNA-Impfung

Immunresponser til COVID-19 vaksiner

Schlechtere Neutralisation der Delta-Variante unter TNF-alpha Blockern

Womit boostern bei fehlender Serokonversion?

Durchbruchsinfektionen nach SARS-CoV2-Impfung - nationale Kohorte

PROs from a real-world study on etanercept biosimilar - 1 year follow-up

CBD - an alternative therapy for chronic pain

Therapeutic drug monitoring - a randomized controlled trial (NOR-DRUM B)

Pearls and myths in rheumatology

Skin findings in patients of color with rheumatic disease

New exciting data - dietary supplements with vitamin D and omega-3 fatty acids

Monitorering av legemiddelkonsentrasjoner (Therapeutic drug monitoring, NOR-DRUM B) – en randomiseret kontrollert studie

Neue spannende Daten - Nahrungsergänzung mit Vitamin D und Omega-3-Fettsäuren